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Introduction: Protease-activated receptors (PARs) evolved to react to extracellular proteolytic activity. In
mammals, three of the four PARs (PAR1, PAR3, and PAR4) that are expressed respond to the prototypical
procoagulant enzyme thrombin, whereas PAR2 was assumed to resist activation by thrombin. To date, in-
volvement of cell surface thrombin-recruiting co-receptors such as thrombomodulin (TM), which potentially
facilitates PAR2 cleavage, has not been addressed. Thus, we examined whether TM-bound thrombin cleaved
PAR2 and tested biological responses such as nuclear factor kappa B (NF-κB) DNA binding activity and cytokine
release.
Materials and methods: We examined 293T cells overexpressing PAR2 and TM for thrombin recruitment by TM
promoting PAR2 cleavage. To test for the TM–thrombin interactions required for PAR2 cleavage and to map
cleavage sites on PAR2, mutant constructs of TM or PAR2 were engineered. Biological eﬀects because of PAR2
activation were investigated using an NF-κB reporter system and cytokine release.
Results and conclusions: We identiﬁed that, at low to moderate concentrations, thrombin cleaved PAR2 in a TM
co-receptor-dependent manner with cleavage eﬃciency comparable to that of trypsin. In TM's presence,
thrombin eﬃciently cleaved both, PAR1 and PAR2, albeit kinetics diﬀered. Whereas the majority of surface
expressed PAR1 was immediately cleaved oﬀ, prolonged exposure to thrombin resulted in few additional
cleavage. In contrast, PAR2 cleavage was sustained upon prolonged exposure to thrombin. However, TM EGF-
like domain 5 was required and TM chondroitin sulfate (CS) proteoglycan sites serine 490 and serine 492 assisted
in PAR2 cleavage, while thrombin preferentially cleaved at arginine 36 on PAR2's N-terminus. Note that
thrombin-induced activation of NF-κB via PAR2 resulted in release of interleukin-8. Thus, we provide a novel
concept of how thrombin eﬃciently cleaves PAR2 in a TM-dependent manner, resulting in pro-inﬂammatory
interleukin-8 release. This unexpected pro-inﬂammatory role of TM, promoting cleavage and activation of PAR2
by thrombin, may lead to novel therapeutic options for treating inﬂammatory and malignant diseases.
1. Introduction
Clotting proteases elicit multiple physiological and pathophysiolo-
gical responses beyond clot formation. The family of PARs has evolved
to allow cells to react to presence of clotting (serine) proteases [1].
PARs belong to the seven-transmembrane G-protein-coupled receptor
family. In mammals, the family of PARs consists of four highly related
serine protease receptors, i.e., PAR1–4 [2–7].
Previously, PAR2 has been linked to inﬂammation-driven diseases
of the brain, cardiovascular system, lungs, joints, and gastrointestinal
tract [8–16], as well as cancer growth [17,18], migration, and
metastasis [9,19]. Despite its importance in pathophysiological pro-
cesses, no treatments based on interference with PAR2 have been es-
tablished [20]. There are potential obstacles for deﬁning therapeutic
targets because of the existence of multiple activation mechanisms and
a large variety of causal activating proteases [21–23], as well as the
complex nature of PAR2 compartmentalization and co-localization
[19]. Recent studies that emphasize the importance of PAR hetero-di-
merization [24], requirement of PAR2 co-localized co-receptors [22],
and introduction of the concept of biased PAR agonists [25] further
demonstrate the complexity of PAR2-related functions under physio-
logical or pathophysiological conditions.
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To date, PAR2 has been assumed to resist activation by the proto-
typical procoagulant protease thrombin, as it has not been observed to
activate overexpressed PAR2 in the absence of co-receptors [1,5,26].
Moreover, only extremely high, potentially supra-physiological con-
centrations of thrombin (up to 500 nM) cleave peptides that are
homologous to PAR2's N-terminus and activate PAR2 [27].
Unlike previous observations of PAR2 resisting thrombin activation,
in vitro and in vivo models have demonstrated multiple eﬀects invol-
ving both, PAR2 and thrombin, such as cancer cell invasion [18], signal
transduction [28,29], and late sepsis. To explain these observations,
PAR1 and PAR2 transactivation is the leading model; the thrombin-
generated N-terminus of PAR1 signaling via a PAR2 hetero-dimer
partner [24,30].
To date, the activation of PAR2 by cofactor (or co-receptor)-bound
thrombin has not been systematically evaluated, although co-receptor-
dependent mechanisms, such as tissue factor-bound clotting factor VIIa
activating PAR2 [22], endothelial protein C receptor-bound activated
protein C (aPC) cleaving PAR1 and PAR3 [31], endothelial protein C
receptor-bound clotting factor Xa cleaving PAR1 [32], and activating
PAR1 or PAR3 [33–35], are well known. Moreover, in mice, PAR3 re-
cruits thrombin which facilitates cleavage of PAR4 [36].
For thrombin-mediated activation of protein C, the cell surface
glycoprotein TM (also known as fetomodulin or CD141) serves as a
cofactor [37,38]. TM is primarily expressed on all vascular endothelial
cells [39], keratinocytes [40], astrocytes [41], monocytes and macro-
phages [42], and lung alveolar epithelial cells [43].
Because TM serves as the key re-director of procoagulant thrombin
[44], which limits clot formation and injury to the vascular bed [45],
TM might play a role in re-directing PAR activation by thrombin in
situations of ongoing thrombin generation such as chronic inﬂamma-
tion. Note that TM-bound thrombin changes substrate speciﬁcity of
thrombin to anticoagulant and anti-inﬂammatory signaling via protein
C activation. TM expression is linked to regulation of homeostatic and
inﬂammatory responses during injuries [46]. For acute injuries of the
endothelium, TM downregulation or shedding occurs; accordingly, so-
luble TM (sTM) serves as a marker for acute inﬂammation [47]. Fur-
thermore, compared with the endothelium, less is known about the TM
co-receptor's function in other tissues.
Therefore, we tested whether TM serves as a co-receptor for the
thrombin-dependent cleavage of PAR2. Moreover, we veriﬁed whether
TM-bound thrombin activation of PAR2 resulted in pro- or anti-in-
ﬂammatory eﬀects.
2. Materials and methods
2.1. Reagents
Thrombin [EC 3.4.21.5] was purchased from Haematologic
Technologies (Essex Junction, VT, USA) and trypsin [EC 3.4.21.4] from
Gibco (Thermo Fisher Scientiﬁc, Reinach, Switzerland). Recombinant
aPC (Xigris) was purchased from Eli Lilly and Company (Indianapolis,
IN, USA). Peptides corresponding to the N-terminus of R41-cleaved
PAR1 (TFLLRNPNDK), R36-cleaved PAR2 (SLIGRL), and PAR4
(AYPGKF) were custom-made (Synpeptide Co., Ltd., Shanghai, China;
and ProteoGenix, Schiltigheim, France).
Recombinant sTM (SRP3172), Nordihydroguaiaretic acid (NDGA),
TNFα and PI3K inhibitor LY294002 were purchased from Sigma (Buchs
SG, Switzerland). We used lepirudin (Reﬂudan; Schering, Berlin,
Germany) to block thrombin. In fact, when added without thrombin,
lepirudin had no eﬀect in any of the reported assays and readouts.
Heparin was purchased from Bichsel (Interlaken, Switzerland).
Thrombin exosite I blocking aptamer (5′-GGTTGGTGTGGTTGG-3′ [48])
and exosite II blocking aptamer (5′-AGTCCGTGGTAGGGCAGGTTGGG
GTGACT-3′ [49]) were custom-made (Microsynth, Balgach, Switzer-
land). Monoclonal anti-PAR1 ATAP2 was used as described previously
[32,50] and anti-PAR2 (SAM11; Thermo Fisher Scientiﬁc), anti-
PAR2_#344222 (MAB3949; R&D Systems, Inc., MN, USA), anti-
TM_#1009 [141C01(1009), Thermo Fisher Scientiﬁc], anti-TM_#2375
(American Diagnostics, Pfungstadt, Germany), anti-TM_#501733
(MAB3947; R&D Systems), anti-His_#AD1.1.10 (MAB050; R&D Sys-
tems), and goat anti-mouse IgG Alexa-594 (R37121; Thermo Fisher
Scientiﬁc) were all used according to manufacturer's instructions unless
stated otherwise. All oligonucleotides were purchased from Microsynth.
For quantifying luciferase activity, the Bright-Glo™ Luciferase Assay
System (Promega, Dübendorf, Switzerland) was used, in accordance to
the manufacturer's instructions.
2.2. Peptide cleavage
A high-binding microplate (#9018; Corning, Tewksbury, MA, USA)
was coated (o/n) with anti-His#AD1.1.10 (2 μg/ml) and anti-
TM_#501733 (1 μg/ml). Then, the plate was washed and incubated
with buﬀer or recombinant sTM (60 nM) to bind to anti-TM for 30min.
Synthetic PAR2 peptide (10 μg/ml) was bound to the plate by the N-
terminal His-tag (1 h). We added pre-warmed thrombin (30 nM) to the
washed plate and incubated the plate for 1 h at 37 °C. The uncleaved
(full length) PAR2 peptide was detected via the C-terminal biotin-tag
using streptavidin-HRP and quantiﬁed by a peroxidase-based enzyme
immunoassay.
2.3. Cell culture, plasmid transfection, and gene silencing
Epithelial A549 cells and human embryonic kidney cell-derived
293T cells (ATCC; LGC Standards GmbH, Wesel, Germany) were culti-
vated and propagated as described previously [32,50]. In brief, cells
were propagated in DMEM (Gibco) containing 10% fetal calf serum (GE
Healthcare, Glattbrugg, Switzerland), detached using dissociation
buﬀer (Gibco), transfected, seeded, and grown to conﬂuence in multi-
well dishes. Two days later, experiments were performed using washed
cells and serum-free conditioning medium (DMEM) containing 0.04%
BSA (Sigma).
Tagged and untagged PAR1, PAR2, TM constructs, and
pGL4.32[luc2P/NF-κB-RE/Hygro] (Promega) were transiently ex-
pressed in 293T cells by transfection with Lipofectamine2000 (Thermo
Fisher Scientiﬁc), as described previously [34]. Cells used for cleavage
assays were transfected with 1.6 μg/ml plasmid DNA; however, for NF-
κB luciferase and IL-8 enzyme-linked immunosorbent assay (ELISA)
assays, 1.0 μg/ml plasmid DNA was used for transfection of the 293T
cells. To reach comparable amounts of PAR2 expression, in those cells
that overexpressed several proteins (such as with and without TM), the
empty pcDNA3.1/Zeo(+) plasmid (Thermo Fisher Scientiﬁc) was used
as a mock plasmid. We performed gene silencing using Lipofectamine
RNAiMAX (Thermo Fisher Scientiﬁc) as described previously [32],
using 20 nM silencing RNA (siRNA). GGAACCAAUAGAUCCUCUAtt (si
PAR2) to silence PAR2 and AGGUAGUGUAAUCGCCUUGtt was used as
a control silencing RNA (si control). Furthermore, all oligonucleotides
were synthetized by Microsynth.
2.4. Overexpression constructs
The overexpression constructs were embedded within the
pcDNA3.1/Zeo(+) (Thermo Fisher Scientiﬁc) expression plasmid, as
described previously [34]. TM was cloned from cDNA (obtained from
RNA isolated from EA.hy926 endothelial cells) using primers con-
taining restriction sites (italics) HindIII and XhoI (forward: 5′-
GCTAAAGCTTGACAGGAGAGGCTGTCGCCATC-3′ and reverse: 5′-GCT
ACTCGAGGGGAATAAGTGGGGCTTGCT-3′). The HindIII/XhoI-digested
PCR product was directly introduced into the HindIII/XhoI-cut
pcDNA3.1/Zeo(+) backbone. For removal of N-terminal domains in
TM, two unique BamHI restriction sites were introduced by mutagen-
esis (NEB's plasmid mutation kit; Ipswich, MA, USA): the ﬁrst 3′ from
the signal sequence and the second 3′ from the sequence that encoded
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the domain to be removed. Digestion of the mutated TM expression
vector with BamHI followed by plasmid re-ligation allowed dropping
domains while maintaining the TM native signal sequence (details are
provided in Supplementary Table S1). Note that TM chondroitin sulfate
(CS) sites serine 490 and 492 were mutated to alanine with the primer
set (forward: 5′-CACGGCTCGACCTCAATG-3′, reverse: 5′-GGGGCTC
GCCAGCGCCGGCGTCGCCACCGTCC-3′).
PAR1 and PAR2 alkaline phosphatase-tagged reporter (“AP-PAR1
and AP-PAR2”) was as described elsewhere [34]. Sequence of the PAR4
alkaline phosphatase-tagged reporter (“AP-PAR4”) is described in
Supplementary Table S4. In brief, an alkaline phosphatase (AP) tag
(pSEAP; Clontech, CA, USA) was linked to the N-terminus of PAR1
cDNA (F2R, NM_001992.4), PAR2 cDNA (F2RL1, NM_005242.5), and
PAR4 cDNA (F2RL3, NM_003950.3). Unlike the PAR2 construct men-
tioned elsewhere [34], an arginine (italics) at the C-terminal end of AP
(potential thrombin cleavage site) was removed using phosphorylated
mutagenic primers (forward: 5′-CCCGGGTTACTCTGCGGCCCAAGGAA
CCAATAG-3′; reverse: 5′-CTATTGGTTCCTTGGGCCGCAGAGTAACCC
GGG-3′; Supplementary Table S2). We inserted a green ﬂuorescent C-
terminal tag (EGFP; Clontech) analogous to a procedure used in a
previous study [34] (for details, see Supplementary Table S2 and Sup-
plementary Scheme S1). To test for preferred cleavage sites on PAR2's
N-terminal, arginine 36 was replaced by alanine (“PAR2 R36A;” protein
sequence in Supplementary Table S3) using mutagenic primers (for-
ward: 5′-CCAATAGATCCTCTAAAGGAGCAAGCCTTATTGGTAAGG-3′;
reverse: 5′-TTCCTTGGGCCGCAGAGTAACCCGGG-3′). Next, all poten-
tial thrombin cleavage sites (arginine and lysine) were replaced by
alanine (“PAR2 all-to-A” mutant; protein sequence provided in Sup-
plementary Table S3). Note that all constructs that were used were
veriﬁed by sequencing.
2.5. PAR cleavage reporter assay
The cleavage reporter assay was performed on 293T cells that
transiently expressing AP-PAR constructs (Supplementary Table S2), as
described elsewhere [32]. In brief, washed cells were incubated with an
agonist (for 20min, or if indicated, for repeated periods of 20min),
supernatants were removed and ﬁltered (cellulose ester ﬁlter; pore size,
0.45 μm), and AP activity was quantiﬁed (1-Step PNPP; Thermo Fisher
Scientiﬁc) by spectrophotometry (Labsystems Multiskan MCC/340;
Fisher Scientiﬁc). For all experiments, AP-PAR expression levels were
conﬁrmed to be comparable among constructs by quantifying AP ac-
tivity of cell surface. Data are presented in optical density (OD) after
subtraction of signals obtained from cells not incubated with the ago-
nist.
2.6. Immunoassays
IL-8 was quantiﬁed by a commercial (R&D Systems) sandwich
ELISA, according to the manufacturer's instructions. In brief, 293T cells
were transfected with plasmid DNA and A549 cells were silenced with
siRNA 48 h prior to incubation with agonists for 24 and 6 h, respec-
tively. Then, IL-8 release was measured in supernatants. As described
previously, cell surface PAR2 and TM were quantiﬁed by cell surface
ELISA [50].
2.7. Immunoﬂuorescence microscopy
EGFP-tagged protein (Supplementary Scheme S1) was over-
expressed using the same protocols as that described for PAR cleavage
reporter constructs and visualized using appropriate ﬁlter sets of an
Axiovert-10 ﬂuorescent microscope (Carl Zeiss AG, Feldbach,
Switzerland). As described for the cell surface ELISA, untagged proteins
were incubated with antibodies; however, the secondary antibody
carried an Alexa-594 ﬂuorescent tag (Thermo Fisher Scientiﬁc) rather
than HRP.
2.8. NF-κB luciferase assay
293T cells were transfected with the NF-κB ﬁreﬂy luciferase con-
struct pGL4.32[luc2P/NF-κB-RE/Hygro] (Promega) along with AP-PAR
constructs and seeded into black, clear-bottomed 96-well plates
(Greiner Bio-One, Kremsmünster, Austria). After transfection for 48 h,
cells were washed and incubated with an agonist (for 6 h) at 37 °C.
Bright-Glo™ Luciferase Assay System reagent was added to cells and
luciferase activity was detected via luminescence (SpectraMax i3;
Molecular Devices, San Jose, CA, USA), according to the manufacturer's
instructions. Furthermore luciferase activity was normalized to the
buﬀer-induced relative light units (RLUs).
2.9. Statistics
We analyzed and presented the data using GraphPad Prism5
(GraphPad Software, La Jolla, CA, USA). To calculate the indicated p-
values, a two-sample, two-tailed homoscedastic t-test and one-way or
two-way ANOVA with Bonferroni correction were used.
3. Results
3.1. Eﬀect of PAR2 activation by thrombin on IL-8 release in native A549
cells
Various studies showed expression of all PARs in lung epithelial
cells promoting IL-8 release upon PAR agonist peptide stimulation due
to PAR cis- or trans-activation [51,52]. In this study, we ﬁrst tested the
concentrations of PAR agonist peptides required to induce IL-8 secre-
tion in A549 cells. Similar to a previous study [53], we found that A549
cells were induced to release IL-8 on incubation with the PAR2 agonist
peptide SLIGRL, whereas the PAR1 agonist peptide TFLLRNPNDK and
the speciﬁc PAR4 agonist peptide AYPGKF demonstrated no such eﬀect,
even at high concentrations. Unlike the PAR1-speciﬁc peptide,
thrombin signiﬁcantly induced IL-8 release from 30 to 100 nM
(Fig. 1A). To test whether thrombin induced IL-8 release could be
linked to PAR2 activation, we relied on the PAR2-speciﬁc inhibitor
NDGA. NDGA did neither aﬀect IL-8 release at baseline (buﬀer control)
nor in highly TNFα-induced A549 cells (not shown). However, NDGA
signiﬁcantly reduced IL-8 release by thrombin as well as by the PAR2-
speciﬁc agonist SLIGRL (Fig. 1B). Consistently, silencing of PAR2 by
siRNA abolished responses of A549 cells to thrombin or SLIGRL in-
duction (Fig. 1C). In summary, IL-8 release by thrombin stimulation
was signiﬁcantly reduced in PAR2-silenced or inhibited lung epithelial
cells, suggesting that thrombin plays a role in PAR2 signaling.
3.2. Role of TM on PAR2 cleavage by thrombin
To test whether IL-8 induction by thrombin in epithelial cells of the
lung could be caused by direct cleavage of PAR2 using a co-receptor, we
established a puriﬁed system comprising immobilized PAR2 peptide
with immobilized sTM and thrombin. In this puriﬁed system, thrombin
eﬃciently cleaved the PAR2 peptide in immobilized sTM's presence;
however, consistent with the established conclusion, thrombin failed to
directly cleave PAR2 in the co-receptor's absence (Fig. 2A). To test on
human cells whether physiologically achievable concentrations of
thrombin cleaved PAR2 and whether co-receptor(s) could be involved,
we relied on the previously established PAR cleavage reporter system
[32,34,54]. To allow veriﬁcation of construct expression by assessing
the tag's cell surface AP activity and monitor cleavage by quantifying
the activity of AP released into the supernatant, we overexpressed PAR2
containing an AP enzyme domain at the N-terminus (Supplementary
Table S2; Supplementary Scheme S1, [34]). PAR2 reporter and TM
constructs were expressed at the cell surface, which was further as-
sessed by ﬂuorescence microscopy and cell surface ELISA. Co-expres-
sion of PAR2 and TM did not aﬀect expression of both constructs
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(Supplementary Fig. S1a and b). In such an overexpression system, free
thrombin at concentrations up to 30 nM failed to cleave PAR2 (Fig. 2B),
unlike the results of a recent study [27]. However, in TM's presence,
cleavage eﬃciency was signiﬁcantly enhanced and, at low nanomolar
concentrations of proteases, thrombin and trypsin showed comparable
cleavage eﬃciency (Fig. 2C). To test whether thrombin/TM could
mediate release or activation of another protease, which ultimately
cleaved PAR2, we added thrombin-induced supernatant from TM-ex-
pressing cells to 1) PAR2- and 2) PAR2- and TM-expressing cells, for
assessing PAR2 cleavage. We identiﬁed that, in the absence of TM,
PAR2 was not cleaved and, wherever thrombin in supernatant was
blocked by the speciﬁc inhibitor lepirudin, cleavage was blunted
(Fig. 2D). Addition of activated protein C or inhibition of metallopro-
teases did not aﬀect PAR2 cleavage by thrombin (Supplementary Fig.
S3a and b). Therefore, overall, these results cannot support a model
whereby thrombin induces a PAR2-cleaving protease. To simulate more
physiological conditions where PAR1, PAR2 and TM are co-expressed,
and to test whether the co-expression impacts cleavage, we over-
expressed 1) PAR1 containing an N-terminal AP enzyme tag together
with untagged-PAR2 or 2) PAR2 containing an N-terminal AP enzyme
tag together with an untagged-PAR1 (Supplementary Table S2;
Supplementary Scheme S1, [34]) in presence or absence of TM. As
expected, PAR1 was rapidly cleaved by thrombin (5 and 30 nM) while
PAR2 - in TM's presence - was more eﬃciently cleaved upon prolonged
thrombin exposure (5 and 30 nM) (Fig. 2E and F). The cleavage of PAR2
at 60min of exposure to thrombin (30 nM) was comparably eﬃcient to
the PAR1 cleavage at 20min (Fig. 2F). Cleavage of PAR2 was sustained
upon prolonged exposure to thrombin for up to 25 h (Supplementary
Fig. S4a–c). Note that, upon a exposure to thrombin for 3 h, a broad
range of thrombin concentrations from 1 to 30 nM resulted in sig-
niﬁcant cleavage of PAR2 (Supplementary Fig. S4a–c). Our observa-
tions suggest that TM-bound thrombin directly cleaves PAR2 in our
overexpression system and that TM dependent cleavage of PAR2 by
thrombin is enhanced over time. Thus, in summary, our data suggest
that thrombin at moderate concentrations (5 and 30 nM) eﬃciently
cleaves overexpressed PAR2 reporter construct in TM's presence.
3.3. Importance of interactions between TM EGF-like domains and CS with
thrombin exosite I and exosite II on PAR2 cleavage
Next, we addressed domains of TM required for increasing PAR2
cleavage by thrombin. TM contains six epidermal growth factor (EGF)-
Fig. 1. Increased IL-8 release upon thrombin and SLIGRL stimulation in a PAR2-dependent manner. (A) A549 cells were stimulated with thrombin, PAR2 agonist
peptide SLIGRL, PAR1 agonist peptide TFLLRNPNDK, and PAR4 agonist peptide AYPGKF for 6 h. Then, IL-8 release was quantiﬁed by a peroxidase-based enzyme
immunoassay. (B) A549 were pretreated with DMSO or NDGA (20 μM) for 30min before stimulation with buﬀer, thrombin or SLIGRL (concentrations indicated in
the graph). IL-8 release in the supernatant was quantiﬁed by ELISA after 6 h of agonist incubation. (C) A549 cells were transfected with siRNA targeting no speciﬁc
mRNA (si control) or siRNA targeting PAR2 (si PAR2). Then, cells were stimulated with buﬀer, thrombin (30 nM), or SLIGRL (50 μM) for 6 h before IL-8 release was
measured in cell supernatants. Data was presented as mean ± SEM; three independent experiments were each performed in triplicate; ns p > 0.05, *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 using one-way ANOVA (A) and student's t-test (B, C).
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like domains, from which EGF-like domain 4 was linked to protein C
substrate acceptance, whereas EGF-like domains 5 and 6 were linked to
thrombin recruitment [55] to the cell surface. To test whether these
EGF-like domains were involved in promoting PAR2 cleavage, we
produced N-terminally truncated mutants of TM (Supplementary Table
S1). The mutants were expressed and recognized as expected by cell
surface ELISA using anti-TM targeting EGF-like domains 5 and 6
(Supplementary Fig. S5). Note that PAR2 was eﬃciently cleaved when
wild-type TM or mutants containing EGF-like domains 5 and 6 were
present. The TM mutant composed of only EGF-like domain 6 failed to
Fig. 2. Thrombin eﬃciently cleaves overexpressed PAR2 in the presence of TM. (A) A PAR2-derived synthetic peptide mimicking the entire extracellular N-terminal
domain of PAR2 was bound to the plate via a C-terminal 6xHis-tag and incubated with thrombin in the presence or absence of immobilized sTM. Uncleaved PAR2 was
detected via ELISA peroxidase-based quantiﬁcation of unremoved N-terminal biotin tags. Stars indicate comparisons of ⁎ PAR2 peptide cleavage of sTM+ thrombin
vs. thrombin without sTM or (⁎) sTM+ thrombin vs. sTM without thrombin. (B) 293T cells transiently overexpressing AP-PAR2 reporter construct either alone or
with TM. Where indicated, cells were incubated with thrombin (30 nM) for 20min before the released AP's activity was measured in the cells' supernatants, serving as
a surrogate for PAR2 cleavage. (C) Cells expressing TM and AP-PAR2 reporter construct were incubated with agonists as indicated and assayed as described in (B).
Stars indicate the comparison of thrombin to buﬀer in cells overexpressing AP-PAR2+TM. (D) 293T cells expressing only TM were incubated with thrombin
(20min, 30 nM). Thereafter, the supernatant was swapped to AP-PAR2- or AP-PAR2 and TM-expressing cells and the cells were incubated for another 20min. Where
indicated, the supernatant was pre-incubated with the thrombin inhibitor lepirudin (30 nM) before it was added to the cells expressing AP-PAR2 or AP-PAR2 and TM.
(E) and (F) 293T cells expressing AP-PAR1 together with non-tagged PAR2 or AP-PAR2 together with non-tagged PAR1 with or without TM were incubated with (E)
thrombin (5 nM) or (F) thrombin (30 nM) for 20min. AP activity was measured in the supernatant and the cells were agonist-incubated for repeated periods of
20min. Stars indicate the comparison of thrombin to buﬀer in cells overexpressing AP-PAR2+PAR1+TM. Data are presented as mean ± SEM; (A–D) three or (E,
F) four independent experiments, each performed in triplicate; ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, using student's t-test.
Fig. 3. For PAR2 cleavage by thrombin, interaction between thrombin exosite I and TM's EGF-like domain 5 is necessary, along with interaction between exosite II
and TM's CS motif. (A) 293T cells overexpressing AP-PAR2 reporter construct alone or together with either wild-type TM (TM) or mutants of TM lacking N-terminal
domain(s). Scheme of the expressed TM domains is provided (bottom of A) and the details are explained in Supplementary Table S1. After 20min of incubation with
thrombin (30 nM), PAR2 cleavage was measured. (B) AP-PAR2 reporter construct was co-expressed in 293T cells with wild-type TM or a TM mutant lacking the CS
sites serine 490 and 492 (TM CS-). Moreover, PAR2 cleavage by thrombin (30 nM) was measured as in (A). (C) 293T cells overexpressing AP-PAR2 and TM were
incubated (for 20min) with buﬀer, thrombin (30 nM), or a mixture of thrombin (30 nM) and exosite blocking aptamers (2 μM); then, PAR2 cleavage eﬃciency was
measured. (D) 293T cells overexpressed AP-PAR2 with or without TM. Where indicated, cells were incubated for 20min with thrombin (30 nM) alone or a 1:1
mixture of thrombin and sTM (20min of pre-incubation at 37 °C for complex formation). Data are presented as mean ± SEM; three independent experiments were
each performed in triplicate; ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, using student's t-test.
D.M. Heuberger, et al. Thrombosis Research 177 (2019) 91–101
96
promote the cleavage of PAR2 by thrombin (Fig. 3A).
Moreover, interactions between thrombin exosite II and CS on TM
were involved for thrombin recruitment [56] and to enhance the en-
dothelial protein C pathway. To test whether such interactions between
exosite II and CS facilitated PAR2 cleavage by thrombin, we synthesized
a TM mutant that lacked the serine 490 and 492 glycosylation sites.
Similar to the conclusions from the protein C pathway that interactions
between exosite II and CS assist with thrombin recruitment toward TM,
CS-deﬁcient mutant of TM was less eﬃcient for supporting the cleavage
of PAR2 by thrombin (Fig. 3B). Similarly, blocking the interactions of
exosite II with CS with an aptamer, a short single-stranded DNA spe-
ciﬁcally blocking exosite II [49], interfered with PAR2 cleavage
(Fig. 3C). Supporting this observation, PAR2 cleavage was reduced by
exosite II binding agent heparin (Supplementary Fig. S2). Unlike exosite
II and TM interaction, the interaction of exosite I with EGF-like domain
5 and 6 of TM is considered essential for thrombin recruitment [57].
Moreover, blocking exosite I by an aptamer [48] blunted PAR2 clea-
vage by thrombin (Fig. 3C).
To test whether sTM supports PAR2 cleavage by thrombin,
thrombin was pre-incubated with recombinant sTM that lacks the
membrane anchor. The mixture was then tested for PAR2 cleavage. In
the absence of cell surface-expressed TM, sTM–thrombin mixture failed
to signiﬁcantly cleave PAR2 (Fig. 3D). This observation supports either
the lack of sTM's role in assisting PAR2 cleavage by thrombin or the
failure of our cells to recruit sTM–thrombin complexes onto the cell
surface.
Thus, similar to our observations of the protein C pathway, our data
suggest that, for eﬃcient PAR2 cleavage by thrombin, interactions
between TM's EGF-like domain 5 and the thrombin exosite I is parti-
cularly important, in addition to the eﬃciency-boosting eﬀect of the
interaction between CS and thrombin exosite II, as well as the essential
role played by cell surface-anchored TM.
3.4. Role of PAR2 N-terminal arginine 36 in cleavage by thrombin
Previous evidence suggested that PARs harbor a unique cleavage
site that promotes initiation of biological eﬀects [1]. Recently, how-
ever, studies have revealed that PARs behave as “multi-switches” with
several cleavage sites, resulting in cleavage-site-speciﬁc biological ef-
fects [23,34,35,58] and referred to as biased signaling. Thus, we in-
vestigated whether TM-bound thrombin cleaved PAR2 at speciﬁc sites.
Similar to our studies in PAR1 and PAR3 [34], we synthesized mutants
of PAR2 with alanine (A) substitutions for the positively charged amino
acids arginine (R) and lysine (K) in the extracellular N-terminal domain
(Supplementary Table S3). A mutant of PAR2 that was devoid of all R
and K on the entire N-terminal domain (“PAR2 all-to-A” mutant; Sup-
plementary Table S3) resisted cleavage by thrombin (Fig. 4A). Removal
of canonical R36 (“PAR2 R36A” mutant; Supplementary Table S3)
yielded an almost thrombin-resistant mutant (Fig. 4B); however, addi-
tional sites at which cleavage occurs ineﬃciently might be present.
Thus, our data suggest that R36 is the preferred cleavage site of TM-
bound thrombin; however, the existence of additional cleavage site(s)
cannot be ruled out.
3.5. Role of the NF-κB pathway downstream of thrombin-cleaved PAR2
Previously, pro-inﬂammatory signaling was reported to occur be-
cause of PAR2 activation by other proteases that cleaved PAR2 at R36
[11–13]. Thus, we investigated whether TM-bound thrombin cleaved
PAR2 and induced pro-inﬂammatory signaling via NF-κB activation. In
our commercial NF-κB reporter system, thrombin failed to induce NF-κB
activation when PAR2 and TM were absent or expressed alone (Sup-
plementary Fig. S6a). NF-κB DNA binding activity, however, increased
in a manner dependent on thrombin concentration due to the avail-
ability of PAR2 and TM (Fig. 5A). PAR2 agonist peptide SLIGRL in-
duced NF-κB DNA binding activity in PAR2 and TM overexpressing cells
similarly to thrombin; however,> 1000 times higher concentrations of
agonist peptide was required to obtain comparable induction (Fig. 5A).
Similar to thrombin, the PAR1 agonist peptide TFLLRNPNDK induced
NF-κB activation only if PAR1 was overexpressed. Similarly, the PAR4
agonist peptide AYPGKF induced NF-κB activation only in cells over-
expressing PAR4. As expected, the PAR4 activation by thrombin was
less eﬃcient compared to PAR1 activation. In the absence of over-
expressed PAR1 or PAR4, agonist peptides showed no such eﬀect, si-
milar to TFLLRNPNDK and AYPGKF failing to activate endogenous
PAR1 or PAR4 in these cells and consistent with TFLLRNPNDK and
AYPGKF failing to activate overexpressed PAR2 in this system. How-
ever, similar to the PAR2 agonist peptide SLIGRL, thrombin-induced
NF-κB activation via PAR2 only in the presence of TM (Supplementary
Fig. S6b).
Moreover, consistent with our conclusions from the PAR2 cleavage
reporter assay, EGF-like domain 5 of TM was required for thrombin-
and PAR2-mediated induction of NF-κB activation (Fig. 5B).
We then tested whether thrombin's preferred cleavage site R36 was
important for NF-κB induction. In R36's absence, our assays showed
diminished cleavage of PAR2 and no induction of NF-κB activation
(Fig. 5C).
We then addressed the signal pathways downstream of PAR2 but
upstream of NF-κB activation. Phosphatidylinositol 3-kinase (PI3K)
pathway is an important regulator of NF-κB activation and potentially
links PAR2 cleavage and activation to the NF-κB pathway. To test
whether the induction of NF-κB activation after PAR2 cleavage oc-
curred via PI3K, we used the PI3K inhibitor LY294002. Consistent with
PI3K linking PAR2 and NF-κB, LY294002 interfered with NF-κB acti-
vation by thrombin and activation by PAR2-speciﬁc peptide SLIGRL
(Fig. 5D).
Note that 293T cells secreted IL-8 with the overexpression of PAR2
and SLIGRL agonist induction. However, as shown previously [34] and
in Supplementary Fig. S6b, cells remained quiescent upon incubation
with the PAR1 agonist peptide, which conﬁrms our previous conclusion
that, without transfection, these cells would not respond to PAR ago-
nists. Note that thrombin-stimulated 293T cells overexpressing PAR2
alone remained quiescent. However, in cells expressing TM and PAR2,
thrombin (30 nM) and SLIGRL (50 μM) were comparably eﬃcient for
inducing the release of IL-8 (Fig. 5E). Thus, our data suggest that PAR2
cleaved at R36 by TM-bound thrombin induced NF-κB DNA binding
activity via PI3K and ultimately released IL-8 release (Fig. 5F).
4. Discussion
Our data show, for the ﬁrst time, eﬃcient TM-dependent direct
cleavage and activation of PAR2 by thrombin. This breaks the dogma of
PAR2 as the only PAR that resists activation by an important clotting
protease thrombin. In a manner dependent on TM co-receptor avail-
ability, eﬃcient PAR2 cleavage occurred even at lower concentrations
of thrombin. Unexpectedly, at low concentrations of proteases, eﬃ-
ciency levels of PAR2 reporter cleavage between thrombin and trypsin
were comparable. PAR2 cleavage by thrombin was - in TM's presence -
comparable to cleavage of PAR1, although kinetics diﬀered. While
PAR1 was rapidly cleaved oﬀ with minimal sustained cleavage, PAR2
cleavage increased over time. Thus, we suggest that PAR1 is responsible
for rapid thrombin responses while PAR2 sustains the thrombin sig-
naling following PAR1 desensitization. In fact, PAR2 cleavage by
thrombin was most eﬃcient at the canonical cleavage site arginine 36.
Note that this study establishes a direct link of cleavage of PAR2 by
thrombin to pro-inﬂammatory signaling such as activation of NF-κB
pathway and release of IL-8 in natively PAR2- and TM-expressing A549
lung epithelial cells. To date, PAR2 has been assumed to be distinct in
the family of PARs in terms of resisting cleavage and activation by
thrombin [1,5,26]. However, biological eﬀects of thrombin have now
been linked to PAR2, although the exact mechanism of activation needs
to be clariﬁed. Transactivation of PAR2 by thrombin-cleaved PAR1 is
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one such standard model [24,59], although it is inconsistent with ob-
servations demonstrating that thrombin maintained signaling via PAR2
under conditions where PAR1's tethered ligand was blocked [9].
As an alternative model, two studies have conﬁrmed extremely high
concentrations of free thrombin directly cleaving PAR2 [27,60]. During
a thrombin burst, the required concentration of thrombin of
100–500 nM is potentially achievable [61]. However, in-depth studies
in mice showed that mice lacking the thrombin platelet surface re-
cruiting receptor PAR3 (a nonfunctional receptor in mice) bleed, which
is not in line with the physiologic occurrence of thrombin concentra-
tions at some hundred nanomolar [62]. Studies involving blocking
antibodies [63] support an upper limit of physiologically relevant
thrombin concentrations of< 30 nM, thus ruling out the physiological
relevance of PAR2 activation at high concentrations of free thrombin.
Similar to our co-receptor-dependent activation of PARs, as shown
in the case of PAR1 by aPC [31] and clotting factor Xa [32], PAR2 by
clotting factor FVIIa [22], or platelet-expressed PAR4 by thrombin [62],
we postulated that, for eﬃcient PAR2 activation by thrombin, a co-
receptor was required. Indeed, we discovered a novel co-receptor
function of TM, supporting the cleavage and activation of PAR2 by
thrombin. Indeed, TM's presence increased thrombin's eﬃciency for
cleaving PAR2. Other potential PAR2 cleaving proteases induced or
activated by thrombin or the thrombin-TM complex were ruled out.
Highlighting the plausibility of the presence of TM playing a physio-
logical role, 5 nM thrombin and 5 nM trypsin cleaved PAR2 with
comparable eﬃciency. Because TM is not the only cell surface receptor
for thrombin [64], other surface recruiting receptors might contribute
to further PAR2 activation by thrombin and explain the PAR2-depen-
dent eﬀects of thrombin in cells that did not express TM. We identiﬁed
that the EGF-like domain 5 of TM and exosite I in thrombin were im-
portant for TM-promoted PAR2 cleavage and NF-κB pathway activation
by thrombin. Furthermore, this conclusion was supported by removing
the EGF-like domains on TM and by blocking thrombin exosite I site
using a small speciﬁc aptamer. Our observations reinforce previous
research on TM [55], showing that in the context of the protein C
pathway the described interaction is required for cell surface recruit-
ment of thrombin. Similarly, interactions between exosite II and CS
help in thrombin recruitment [57]. Furthermore, we found that exosite
II blocking aptamers or exosite II binding heparin interfere with PAR2
cleavage by thrombin. These results are in accordance with a recently
published study that links the TM glycosaminoglycan domain to im-
mune responses [65].
Thus, our data conﬁrms that thrombin activates NF-κB and induces
IL-8 release for overexpressing 293T cells and triggers IL-8 release in
A549 cells in a TM- and PAR2-dependent manner. The speciﬁc PAR2
agonist SLIGRL induced IL-8 release, supporting PAR2 stimulation to be
suﬃcient for IL-8 release. Complementary, interfering with PAR2 either
via inhibition (NDGA) or knock down (siRNA) signiﬁcantly reduced
responsiveness to thrombin and SLIGRL of natively PAR2 expressing
A549 cells. Although thrombin-induced IL-8 release was signiﬁcantly
reduced in PAR2 silenced or inhibited cells, we failed to render our
system fully thrombin irresponsive. Possible explanations include in-
complete PAR2 knock down, or another (yet to be identiﬁed) thrombin
receptor induced IL-8 release.
With such a well-characterized system, we provided evidence that
co-receptor-bound thrombin directly activates pro-inﬂammatory path-
ways via PAR2. Our evidence conﬁrms that A549 cells did not release
IL-8 on stimulation with PAR1 agonist peptide. This result is consistent
with that of a recent study [53]. Our results support that prolonged
thrombin signaling via PAR2/TM could explain pro-inﬂammatory sig-
naling in A549 alveolar cells. In view of thrombin inhibition amelior-
ating chronic inﬂammation of the lung as reviewed in [66] one is
tempted to speculate, that thrombin/TM/PAR2 might serve as under-
lying mechanism. Thus, stimulation of PAR2 by extravascular thrombin
might contribute to inﬂammatory diseases of the lung.
Our conclusion that thrombin activates PAR2 via the co-receptor
TM is heavily reliant on overexpression systems; thus, the physiological
relevance of this has yet to be established completely. The conﬁrmation
of our concept in a single cell line, i.e., A549 natively expressing PAR2
and TM, cannot eliminate this important limitation. However, to sum-
marize, we provide the ﬁrst evidence that TM-bound thrombin cleaves
and activates PAR2 eﬃciently at low to moderate nanomolar con-
centrations and that this pathway of NF-κB activation results in the
release of IL-8 in PAR2- and TM-overexpressing and natively expressing
cells. Further studies will be required to link this novel signaling
pathway to important pathophysiological processes, particularly for
chronic inﬂammatory diseases such as asthma, arthritis, and cancer.
Note that such studies may reveal novel therapeutic strategies for dis-
eases that are linked to PAR2.
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Fig. 5. NF-κB DNA binding activity and IL-8 release is induced by TM-bound thrombin in a PAR2-dependent manner. (A) 293T cells carrying an NF-κB reporter
overexpressed either AP-PAR2 alone or AP-PAR2 together with TM, were incubated with an agonist as indicated and quantiﬁed for NF-κB luciferase activity by
measuring luminescence. Arrows indicate thrombin (30 nM) and SLIGRL (50 μM), concentrations used in further NF-κB reporter assays. (B) Cells overexpressing NF-
κB reporter, AP-PAR2 together with wild-type TM, a mutant of TM lacking all domains at the N-terminal side of EGF-like domain 5 (“TM EGF 5–6”), or a mutant
lacking all domains at the N-terminal side of EGF-like domain 6 (“TM EGF 6”). Induction of NF-κB luciferase activity in response to the buﬀer, thrombin (30 nM), and
SLIGRL (50 μM) was also measured. (C) Cells overexpressing NF-κB reporter, TM, and either AP-PAR2 wild-type or AP-PAR2 mutants that lacked all positively
charged N-terminal amino acids (“AP-PAR2 all-to-A”) or only arginine 36 (“AP-PAR2 R36A”). Cells were incubated with buﬀer, thrombin (30 nM), and SLIGRL
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supernatant. (F) Scheme of proposed PAR2 activation pathway: thrombin (IIa) binds to TM, cleaves PAR2, and activates the NF-κB pathway via PI3K activation. NF-
κB activation induces IL-8 synthesis and release. Data are presented as fold induction of buﬀer RLU, presented as mean ± SEM; three independent experiments were
each performed in triplicate; *p < 0.05, **p < 0.01, ***p < 0.001, using two-way ANOVA (B, C, E), one-way ANOVA (A, D).
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